![]() |
|
|
Vol. 30, Issue 2, 135-140, February 2002
Pfizer Global Research and Development, Ann Arbor, Michigan
Bergamottin, a furanocoumarin isolated from grapefruit juice, was
investigated for the ability to increase diazepam bioavailability and
for its effect on cytochrome P450 (P450) enzymes in the beagle dog liver and intestine. To study the effect of bergamottin on diazepam
pharmacokinetics, male beagle dogs were dosed with bergamottin (1 mg/kg) p.o. 0 or 2 h before p.o. diazepam (10 mg). In a second experiment, bergamottin (0.1 mg/kg) was dosed i.v. or p.o. 1 h before p.o. diazepam (10 mg). Plasma samples were collected over 24 h postdose, analyzed by liquid chromatography/mass tandem
spectrometry, and diazepam pharmacokinetic parameters were
determined. To study the effect of bergamottin on P450 enzymes, beagle
dog liver and jejunum was harvested after a 10-day dosing regimen of
bergamottin (1 mg/kg) p.o. per day; microsomes were prepared and
analyzed for CYP3A12, CYP2B11, CYP1A1/2, and tolbutamide hydroxylase
activity. Bergamottin predosing increased the plasma levels of diazepam as observed by Cmax (278.75 ng/ml versus
5.49 ng/ml) and the area under the curve [AUC(0-TLDC)]
(247.69 versus 2.79 ng · hr/ml) in bergamottin versus placebo
groups, respectively, indicating P450 enzyme inhibition. Diazepam
plasma concentrations were increased to a similar level in the presence
of i.v. and p.o. administered bergamottin. In hepatic microsomes,
bergamottin treatment for 10 days reduced the activity of CYP3A12 by
50% and CYP1A1/2 by 75%. Tolbutamide hydroxylase activity did not
change, and CYP2B11 activity was moderately induced. In jejunal
microsomes, CYP3A12 activity doubled with bergamottin treatment.
CYP2B11, CYP1A1/2 activity and tolbutamide hydroxylation was not
detected. In conclusion, bergamottin is both an inhibitor and an
inducer of P450 enzymes.
This article has been cited by other articles:
![]() |
F. Qiu, R. Zhang, J. Sun, J. A, H. Hao, Y. Peng, H. Ai, and G. Wang Inhibitory Effects of Seven Components of Danshen Extract on Catalytic Activity of Cytochrome P450 Enzyme in Human Liver Microsomes Drug Metab. Dispos., July 1, 2008; 36(7): 1308 - 1314. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F Paine, W. W Widmer, S. N Pusek, K. L Beavers, A. B Criss, J. Snyder, and P. B Watkins Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine Am. J. Clinical Nutrition, April 1, 2008; 87(4): 863 - 871. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tibbitts Issues Related to the Use of Canines in Toxicologic Pathology--Issues With Pharmacokinetics and Metabolism Toxicol Pathol, January 1, 2003; 31(1_suppl): 17 - 24. [Abstract] [PDF] |
||||
![]() |
Y. H. Wen, J. Sahi, E. Urda, S. Kulkarni, K. Rose, X. Zheng, J. F. Sinclair, H. Cai, S. C. Strom, and V. E. Kostrubsky Effects of Bergamottin on Human and Monkey Drug-Metabolizing Enzymes in Primary Cultured Hepatocytes Drug Metab. Dispos., September 1, 2002; 30(9): 977 - 984. [Abstract] [Full Text] [PDF] |
||||